Skip to main content

Table 5 The results of subgroup analysis

From: Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors

Comorbidities Hubei OR (95%CI) non-Hubei OR (95%CI) total OR (95%CI)
Hypertension 1.79 (1.46–2.19) 2.96 (2.17–3.35) 2.13 (1.81–2.51)
Diabetes 2.09 (1.76–2.47) 3.25 (2.48–4.26) 2.49 (2.10–2.96)
Cardiovascular diseases 2.43 (1.90–3.09) 3.32 (2.08–5.29) 2.76 (2.18–3.49)
COPD 2.78 (2.09–3.69) 4.60 (2.34–9.06) 3.14 (2.35–4.19)
Malignancy 2.46 (1.27–4.78) 3.32 (1.77–6.23) 2.63 (1.75–3.95)
Chronic liver diseases 1.12 (0.71–1.78) 1.53 (0.99–2.37) 1.32 (0.96–1.82)
Chronic kidney diseases 2.95 (1.51–5.79) 6.28 (3.05–12.94) 3.60 (2.18–5.94)
Cerebrovascular diseases 3.64 (2.32–5.72) 3.87 (1.81–8.29) 3.70 (2.51–5.45)